Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH:ubiquinone oxidoreductase subunit B1 pseudogene 2 (NDUFB1P2) is classified as a human **pseudogene**, meaning it is a segment of DNA similar to a functional gene (NDUFB1), but generally considered **non-coding and functionally inactive**[13][15]. Pseudogenes like NDUFB1P2 may arise from gene duplication or retrotransposition and usually **do not produce functional proteins**. This gene is not associated with any known enzyme activity, molecular function, or disease phenotype, and it is not considered a target for drugs or therapeutic intervention[13][15][11]. Biological function, disease roles, drug interactions, mechanisms of action, biomarkers, or notable safety concerns have not been identified for this pseudogene. **Key distinction:** While NDUFB1 (without the "P2" suffix) encodes a subunit of mitochondrial Complex I involved in the electron transport chain[1][2], NDUFB1P2 is only a non-functional, non-coding sequence. Its presence is mainly relevant to genomic annotation and evolutionary studies, not biomedical targeting or therapeutic development[13][15].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH:ubiquinone oxidoreductase subunit B1 pseudogene 2 (NDUFB1P2).